The role of the UKCRC Registered CTU Network’s International Registration Review Committee (IRRC) is to undertake and have oversight of the Network’s Registration process. In brief, this process assesses the Clinical Trials Unit’s expertise, experience and capability in the design conduct and analysis of clinical trials in the UK. Registration acts as a hallmark of quality, excellence and integrity and provides assurance to the standard of studies undertaken by Registered units. The Committee’s members have extensive expertise in undertaking robust clinical trials at a high-level.
We are currently recruiting a new International Registration Review Committee chair. To view the information for applicants, please click here.
Dr Ian Hudson – Outgoing Chair
Dr Ian Hudson, Senior Advisor, Integrated Development, Global Health, Bill and Melinda Gates Foundation since 2019. Dr Ian Hudson practiced as a paediatrician before working in clinical research and development at SmithKline Beecham for 11 years. Subsequently, in 2001, he joined the MHRA as Director of Licensing and was the UK delegate to EMA’s scientific committee, CHMP, latterly its Vice Chair. Also Honorary Senior Lecturer in Clinical Pharmacology, University of London. In 2013 Dr Hudson became CEO of the MHRA until he retired in 2019. He was also a member of the EMA management Board and part of the Heads of Medicines Agencies Management Group between 2013 and 2019 and Chair of the International Coalition of Medicines Regulatory Authorities between 2016 and 2019. Awarded OBE in New Year’s Honours, 2020 for Services to Healthcare, Faculty of Pharmaceutical Medicine President’s medal for contribution to Pharmaceutical Medicine (2020) and Global Fellow in Medicines Development (2020).
Prof Deborah Ashby – Interim Chair
Professor Deborah Ashby is Director of the School of Public Health at Imperial College London where she holds the Chair in Medical Statistics and Clinical Trials, and was Founding Co-Director of Imperial Clinical Trials Unit. She is a Chartered Statistician and her research interests are in clinical trials, risk-benefit decision making for medicines, and the utility of Bayesian approaches in these areas.
She is the immediate Past President of the Royal Statistical Society. She has sat on the UK Commission on Human Medicines and acted as adviser to the European Medicines Agency. She has recently chaired the Population Research Committee for Cancer Research UK and the National Institute for Health Research HTA Commissioning Board, and was Deputy Chair of the HTA Programme. Deborah was awarded the OBE for services to medicine in 2009, appointed an NIHR Senior Investigator in 2010, and elected to the Academy of Medical Sciences in 2012.
